---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-001222"
form_type: "8-K"
ticker: "HBIO"
cik: "0001123494"
company_name: "HARVARD BIOSCIENCE INC"
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:08:41.637351+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Harvard Bioscience Q4 2023 revenue $28.2M, guides 2024 flat-to-modest growth, margin improvement

## Summary
- Q4 revenue $28.2M, down 1% YoY; gross margin 58.0%, up 230 bps YoY.
- Q4 net loss $1.8M, adj. EPS $0.04; adj. EBITDA $3.6M (13% margin).
- FY2023 revenue $112.3M, down 1% YoY; adj. EBITDA $14.6M (13% vs 9.6% prior year).
- Debt reduced by $10.5M in 2023; net leverage improved from 4.0x to 2.3x.
- 2024 guidance: flat to modest revenue growth; gross margin ~60%; adj. EBITDA margin mid-teens.

## SEC filing metadata
- accession: 0001171843-24-001222
- form_type: 8-K
- ticker: HBIO
- cik: 0001123494
- company_name: HARVARD BIOSCIENCE INC
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/0001171843-24-001222-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/f8k_030624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-001222
- JSON: https://secwatch.observer/filing/0001171843-24-001222.json
- Plain text: https://secwatch.observer/filing/0001171843-24-001222.txt

## Key facts
- Earnings Releases
  HARVARD BIOSCIENCE INC reported the fourth quarter ended December 31, 2023 results: revenue $28.2 million, net income $(1.8) million, EPS $(0.04) per diluted share.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $28.2 million
  - Net income: $(1.8) million
  - EPS: $(0.04) per diluted share
  - Result: reported results
  source text: a filing. --- EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 exh_991.htm EXHIBIT 99.1 Exhibit 99.1 Harvard Bioscience Announces Fourth Quarter 2023 Financial Results · Q4 Revenues of $28.2 million · Q4 Gross Margin of 58.0% (230 bps year-over-year improvement) · Q4 operating income of $0.3 million, adjusted operating income of $3.3 million · Strong operating cash flow
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/0001171843-24-001222-index.htm
- Earnings Releases
  HARVARD BIOSCIENCE INC reported the fiscal year ended December 31, 2023 results: revenue $112.3 million, net income $(3.4) million, EPS $(0.08) per diluted share. Guidance initiated.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $112.3 million
  - Net income: $(3.4) million
  - EPS: $(0.08) per diluted share
  - Guidance: initiated
  - Result: reported results
  source text: in the same period last year. Debt was reduced by $2.3 million during the quarter. Year Ended December 31, 2023 Highlights For the year ended December 31, 2023, revenues were $112.3 million, compared to $113.3 million in the same period a year ago. Revenues for the year include a net reduction of $5.0 million from discontinued products compared to 2022. Gross margin
  evidence_url: https://www.sec.gov/Archives/edgar/data/1123494/000117184324001222/0001171843-24-001222-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.